Objective This study was to develop a 99m Tc-labeled a-methyl tyrosine (AMT) using L,L-ethylenedicysteine (EC) as a chelator and to evaluate its potential in breast tumor imaging in rodents.
Tc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer
Tc-labeled a-methyl tyrosine (AMT) using L,L-ethylenedicysteine (EC) as a chelator and to evaluate its potential in breast tumor imaging in rodents.
Methods EC-AMT was synthesized by reacting EC and 3-bromopropyl AMT (N-BOC, ethyl ester) in ethanol/ potassium carbonate solution. EC-AMT was labeled with 99m Tc in the presence of tin (II) chloride. Rhenium-EC-AMT (Re-EC-AMT) was synthesized as a reference standard for Tc-EC-AMT for 0-2 h. To investigate the transport mechanism, the same cell line was used to conduct the competitive inhibition study using L-tyrosine. Tissue distribution of 99m Tc-EC-AMT was determined in normal rats at 0.5-4 h. Planar imaging of breast tumor-bearing rats was performed at 30 and 90 min. The data were compared with those of 18 F-2-fluoro-2-deoxyglucose. Blocking uptake study using unlabeled AMT was conducted to investigate the transport mechanism of 99m Tc-EC-AMT in vivo.
Results Structures of EC-AMT and Re-EC-AMT were confirmed by nuclear magnetic resonance, high performance liquid chromatography and mass spectra.
In-vitro cellular uptake of 99m Tc-EC-AMT in 13 762 cells was increased as compared with that of 99m Tc-EC and could be inhibited by L-tyrosine. Biodistribution in normal rats showed high in-vivo stability of 99m Tc-EC-AMT.
Planar scintigraphy at 30 and 90 min showed that 99m Tc-EC-AMT could clearly visualize tumors. 99m Tc-EC-AMT uptake could be significantly blocked by unlabeled AMT in vivo.
Conclusion
The results indicate that 
Introduction
Positron emission tomography (PET), using 18 F-2-fluoro-2-deoxy-glucose (FDG), is a gold standard for tumor detection and staging. Unfortunately, FDG has several limitations that give rise to false positive/negative diagnosis and poor predictive value of tumor response to chemo/ radio therapy [1] . FDG has poor contrast in brain tumor because of the high uptake of glucose in both normal and neoplastic brain tissues [2] , and it has poor differentiation of tumor from inflammatory tissue because of the high uptake of FDG in granulocytes and macrophages [3, 4] . Radiolabeled amino acids show relatively low accumulation in normal tissues, rather high accumulation in tumor tissue, and rapid blood clearance. These radiolabeled amino acids are attractive as the main determinant of their uptake are amino acid transporters that are upregulated in cancer cells [5, 6] . Upregulated amino acid transporters indirectly reflect elevated cell proliferation [7] , and assessment of their activities promises potential applications in differential diagnosis and prediction of early treatment response. Among all the radiolabeled amino acids, aromatic amino acids are more suitable for tumor imaging because of easier chemical modification and characterization. However, aromatic amino acids tend to be decarboxylated [8] , which reduces their ability to enter cells through amino acid transporters. Placing a methyl group at the a position could slower their metabolism; thus, greater effort was directed towards the ]iodo-amethyltyrosine [13] .
Clinical study in lung cancer patients showed that FAMT had no false positives in the detection of primary tumors and lymph node metastases, and was able to improve the diagnostic performance in nonsmall cell lung cancer [11] . FAMT has been proven to be transported into the tumor cells solely through the L-type amino acid transporter system (LAT), especially the LAT1 subtype [5] . LAT is the only system that can transport large neutral amino acids with aromatic rings such as tyrosine, phenylalanine and tryptophan [14, 15] . LAT family is known to form heterodimers, which contain a chaperone-like heavy chain 4F2hc and a 12-time transmembrane light chain that is unique to each subtype [16] . Earlier clinical studies showed that uptake of FAMT in tumors was closely correlated with LAT1 expression and cell proliferation [11] . Although FAMT-PET shows very promising clinical results, the radiosynthetic yield is relatively low and the cost of using PET isotope 18 F is prohibitive. Therefore, it is desirable to develop a radiotracer with a simpler chemistry and affordable isotope, which can be used clinically in most major medical facilities.
Technetium-99m ( 99m Tc) is an ideal radioisotope for diagnostic imaging studies because of its physical characteristics. It emits a 140 keV g-ray in 89% abundance [17] , which is commonly used by single photon emission computed tomography. The half-life of 99m Tc is 6.02 h, which can provide serial images and therefore overcome the drawback of 18 F. Diaminodithiol compounds are known to form considerably stable Tc(V) O-complexes owing to the efficient binding of the oxotechnetium group to two thiols and two amine nitrogen atoms [18] . L, L-ethylenedicysteine (EC) is the most successful example of diaminodithiol chelates [19, 20] . We reported earlier that EC conjugates through a peptide bond can be labeled with 99m Tc efficiently with high radiochemical purity and the complex remains stable for several hours [20] . Here, we report the synthesis of 99m Tc-labeled a-methyl tyrosine (AMT) using EC as a chelator and the evaluation of its potential use in breast tumor imaging. Compound 1 (15.48 g; 69.35 mmol) was dissolved in anhydrous dichloromethane (200 ml). Di-tert-butyl dicarbonate (15.14 g; 69.35 mmol) and NaHCO 3 (58.3 g, 0.69 mol) were added. The reaction mixture was stirred overnight at 501C, and the white solid was removed by filtration. The solution was washed with water and dried over anhydrous MgSO 4 . The product was purified by column chromatography using a silica gel column and eluted with hexane/ ethyl acetate (5 : 2 v/v) to yield 8.97 g (40%). MS (m/z):
Materials and methods
Compound 2 (9.42 g; 0.029 mol) was dissolved in acetone (200 ml). 1,3-Dibromopropane (11.0 ml; 0.115 mol) and K 2 CO 3 (10.0 g; 0.178 mol) were added under nitrogen. The reaction mixture was refluxed at 70-801C overnight. After cooling and filtration, the solvent was removed under reduced pressure and the residue was dissolved in chloroform. The residue was washed with water and dried with anhydrous MgSO 4 . The product was purified by column chromatography using a silica gel column and eluted with hexane/ethyl acetate (4 : 1 v/v) to yield 11.0 g (86%). MS (m/z): 445. 10 
EC (3.33 g, 12.4 mmol) was dissolved in water (50 ml), and the pH was adjusted to 9-10 by NaOH (1 N). Compound 3 (3.86 g, 8.69 mmol) in ethanol (80 ml) was added to the above solution, followed by adding K 2 CO 3 (8.6 g, 62.2 mmol). The reaction mixture was then heated at 901C overnight. After cooling, the solvent was removed under reduced pressure and the residue was dissolved in chloroform (50 ml). The residue was washed with water, dried with anhydrous MgSO 4 and evaporated to dryness. Without further purification, compound 4 was used for the following steps.
The crude product of compound 4 (2.5 g, 0.04 mol) was dissolved in dichloromethane (50 ml). Hydrobromic acid (48%, 4.5 ml) was added drop-wise to the solution over a 30 min-period at room temperature with stirring. After filtration, the white solid was washed with ethanol and recrystallized in water to yield 2.08 g (86%).
Rhenium-O-[3-(N-ethylenedicysteine) propyl]-a-methyl tyrosine (compound 6)
An ethanol solution (10 ml) containing trichlorooxobis (triphenylphosphine) rhenium(V) (110 mg, 0.13 mmol) was added to an aqueous solution (10 ml) with O-[3-(Nethylenedicysteine) propyl]-a-methyl tyrosine (EC-AMT) (66 mg, 0.13 mmol) and potassium hydroxide (120 mg, 1.3 mmol), followed by refluxing at 901C for 1 h. The color of reaction mixture changed from green to yellow. After cooling and filtration, the ethanol was removed in vacuo. EC-AMT (1 mg) was dissolved in 0.2 ml sterile water, followed by adding tin(II) chloride (0.1 ml, 1 mg/ml). For EC labeling, EC (0.5 mg) was dissolved in 0.2 ml sterile water by adding 10 ml of 1 N NaOH (pH = 9). The required amount of Na 99m TcO 4 was added to EC or EC-AMT solution (pH 7.4). Radiochemical purity was determined by radio-HPLC (Waters, Milford, Massachusetts, USA) and eluted with acetonitrile:water (7 : 3) using a flow rate of 0.5 ml/min. Tc-EC (0.025 mg/well, 8 mCi/well) or FDG (8 mCi/ well) for 0-2 h. After incubation, the cells were washed with ice-cold PBS twice and detached by adding 0.5 ml of trypsin. The cells were then collected and the radioactivity was measured with a g-counter (Cobra Quantum; Packard, Minnesota, USA). Data were expressed in mean ± SD percentage of cellular uptake (%Uptake).
Competitive inhibition study of 99m Tc-EC-AMT
To investigate the transport mechanisms of 99m Tc-EC-AMT, the competitive inhibition study using L-tyrosine was conducted. Rat breast tumor cells were co-incubated with 99m Tc-EC-AMT (8 mg/well, 8 mCi/well) and L-tyrosine or 99m Tc-EC (4 mg/well, 8 mCi/well) and L-tyrosine for 1 h. A set of concentrations of L-tyrosine (1x, 10x, 50x, and 100x of the 99m Tc-EC-AMT concentration) were used. After incubation, the cells were washed with icecold PBS twice and detached by adding 0.5 ml of trypsin. The cells were then collected and the radioactivity was measured by a g-counter. Data were expressed in mean ± SD %Uptake.
In-vivo tissue distribution studies
All animal studies were carried out in the Small Animal Imaging Facility at UTMDACC under a protocol approved by the Institutional Animal Care and Use Committee. Tissue distribution studies of 99m Tc-EC-AMT (study I, n = 9), FDG (study II, n = 9) or 99m Tc-EC (study III, n = 9) were conducted by using normal female Fischer 344 rats (150 ± 25 g, n = 18) (Harlan Sprague-Dawley, Indianapolis, Indiana, USA). For each compound, the rats were divided into three groups for three time intervals (0.5, 1, 4 h for 99m Tc-EC-AMT and 99m Tc-EC; 0.5, 1, 2 h for FDG; n = 3/time point). The injection activity was 25 ± 0.5 mCi/rat intravenously. At each time interval, the rats were killed and the selected tissues were excised, weighed and counted for radioactivity by a g-counter.
Each sample was calculated as percentage of the injected dose per gram of tissue wet weight. Counts from a diluted sample of the original injection were used as reference. Tc-EC (0.15 mg/rat, 300 mCi/rat; n = 3), respectively. The images were acquired up to 4 h after the administration of tracers. Computer-outlined regions of interest (in counts per pixel) between the tumor and muscle were used to calculate tumor/muscle (T/M) ratios. Micro-PET imaging of FDG was performed using an R4 micro-PET scanner (Concorde Microsystems, Tennessee, USA). The rats were injected intravenously with FDG (500 mCi/rat), and whole body images were acquired at 45 min. PET images were reconstructed by using the ordered subset expectation maximization algorithm.
In-vivo uptake blocking studies
To ascertain whether 99m Tc-EC-AMT uptake is mediated specifically by LAT, in-vivo blocking studies using the unlabeled AMT as the competitive inhibitor were conducted. The same animal model used in the planar imaging studies was used. Unlabeled AMT (50 mg/kg) dissolved in 0.3 ml saline was administered intravenously to mammary tumor-bearing rats 1 h before the 99m Tc-EC-AMT injection. Planar scintigraphic images were acquired up to 4 h, and regions of interest of the tumor, muscle, liver, and kidneys were used to calculate the ratios of liver/muscle, kidney/muscle, and T/M, respectively. The results were compared with those from the rats injected with 99m Tc-EC-AMT alone (control).
Results
Chemistry EC-AMT was synthesized through a five-step procedure. The synthetic scheme is shown in Fig. 1 EC-AMT labeled with 99m Tc was achieved with high radiochemical purity (95%) (Fig. 2) . The retention time of 99m Tc-EC-AMT matched to that of the cold reference standard Re-EC-AMT (Fig. 2) .
In-vitro cellular uptake of 99m Tc-EC-AMT
The cellular uptake kinetics of 99m Tc-EC-AMT, 99m Tc-EC, and FDG using rat breast tumor cells is shown in Fig. 3 . The uptake of 99m Tc-EC-AMT into the 13 762 mammary tumor cells initially increased rapidly and reached saturation at 1 h (0.33%). In addition, the %Uptake of 99m Tc-EC-AMT was dramatically higher than that of the negative control, 99m Tc-EC (0.01%), and relatively higher than that of FDG (0.26%).
Competitive inhibition study of 99m Tc-EC-AMT
After incubation with L-tyrosine at 1-100 times as high as the concentrations of EC-AMT and EC, only 99m Tc-EC-AMT and not 99m Tc-EC showed a significantly decreased uptake (Fig. 4) . These results indicate that 99m Tc-EC-AMT and L-tyrosine are transported through the same transporter system LAT.
In-vivo tissue distribution studies
The tissue distribution results of 99m Tc-EC-AMT, FDG, and 99m Tc-EC in the normal Fischer 344 rats are shown in Tables 1-3 , respectively. Low thyroid uptakes of (Tables 1 and 2 ).
Planar scintigraphic imaging and micro-PET imaging
Planar scintigraphic images of 99m Tc-EC-AMT and 99m Tc-EC control at 30 and 90 min, and the micro-PET image of FDG at 45 min in breast tumor-bearing rats are shown in Fig. 5 . T/M ratios of 99m Tc-EC-AMT were 2.72 and 3.31, whereas those of 99m Tc-EC were 1.95 and 1.81, respectively. Tumors could be clearly detected by both 99m Tc-EC-AMT and FDG, but not 99m Tc-EC (Fig. 5) . 
In-vivo uptake blocking studies
The in-vivo uptake blocking study using unlabeled AMT at 30 and 90 min in breast tumor-bearing rats are shown in Fig. 6 . At 30 min, 99m Tc-EC-AMT uptake in the liver, kidney and tumor decreased by 9.8, 47.9 and 23.9%, respectively by using the blocking agent AMT. However, after 90 min, no significant blocking effect was observed. (Results at 4 h are not shown). These results suggest that 99m Tc-EC-AMT uses the same transport system LAT as AMT does, and is taken up by the tumor rapidly.
Discussion
This study investigated the imaging capability of 99m Tc-EC-AMT in breast tumor-bearing rats. In addition, the transport mechanism was examined both in vitro and in vivo. For chemical synthesis, the precursor EC-AMT was successfully synthesized with an overall yield of 23%. As the chelator EC was unprotected, each EC molecule could be conjugated with more than one AMT, and AMT might not only be conjugated with EC specifically on the nitrogen atom but also on the sulfur atom. Those two potential problems could be readily solved by conducting the coupling reaction in the mild aqueous solution instead of the organic one. In addition, the molar ratio of EC and N-t-butoxycarbonyl-O-[3-Br-propyl]-a-methyl tyrosine ethylester (compound 3) was controlled accurately in 2 : 1 under this aqueous solution. Moreover, the structure of EC-AMT could be well confirmed from the 1 H-NMR and mass spectra results.
When labeling the precursor EC-AMT with 99m Tc, the radiochemical purity was 95%. With respect to that, 99m Tc-EC-AMT is a kit-product and can be labeled without any further purification; the radiochemical yield was assumed to be identical to its radiochemical purity (95%). Re-EC-AMT was synthesized as the reference standard for the structural confirmation of 99m Tc-EC-AMT. In the periodic table, Tc is a second-row transition element in group 7 and is placed directly above Re. Hence, the chemistry of Tc and Re is very similar, and they are known to have identical coordination parameters with the same ligands such as AMT [17] . From the HPLC results, the retention time of Tc-EC-AMT matched that of Re-EC-AMT, suggesting that the radiochemical structure of 99m Tc-EC-AMT was correct. In addition, one radioisotope of Re, 188 Re, is commonly used for internal radionuclide therapy [21] . 188 Re-EC-AMT may have value in the treatment of breast cancer, whereas 99m Tc-EC-AMT can be used to diagnose the cancer and monitor its treatment.
In the cellular uptake study, Tc-EC-AMT was taken up rapidly by 13 762 mammary tumor cells and then reached a plateau (Fig. 3) . The percentage of cellular uptake of 99m Tc-EC-AMT was significantly higher than that of the negative control 99m Tc-EC. Although there was no remarkable cellular uptake difference between 99m Tc-EC-AMT and FDG, EC-AMT showed a potential benefit over FDG because it could be chelated with various radioisotopes such as I-labeled AMT [13, 23] , 18 F-labeled tyrosine [24] , AMT [5] , and fluoroethyltyrosine [25] have been proven to be predominantly transported through the amino acid transporter LAT. Increased expression level of LAT has been observed in various types of tumors [15] , therefore, upregulated LAT is a suitable target for tumor imaging. At the highest 100 times L-tyrosine concentration, both Tc-EC showed a decrease in uptake. This is probably because of cell death caused by the nonspecific cytotoxicity of the extremely high concentration of L-tyrosine.
In planar imaging studies shown in Fig. 5 , the organs in the upper abdominal region (liver and kidneys) showed intense activity of 99m Tc-EC-AMT as indicated by arrows. The biodistribution study showed that both 99m Tc-EC-AMT (Table 1) and 99m Tc-EC (Table 2 ) had high uptake in the liver and kidneys, which was consistent with the results from the imaging study. One possible reason for the high 99m Tc-EC-AMT uptake in kidneys is because of the characteristics of EC given that 99m Tc-EC is known as a renal tubular imaging agent [26] . In addition, Moore et al. [27] reported that AMT itself, an inhibitor of tyrosine hydroxylase, could not be excreted from kidneys, and hence crystallized in the proximal tubules because of its poor solubility at the hydrogen ion concentrations of body fluids (pH 5-8). Furthermore, Shikano et al. [28] confirmed that the uptake of 123 Tc-EC-AMT uptake is mediated specifically by LAT, we then conducted the similar in-vivo uptake blocking studies using the unlabeled AMT as the competitive inhibitor (Fig. 6) .
99m Tc-EC-AMT uptake in the liver, kidney, and tumor were significantly blocked by unlabeled AMT at early time points, which suggested that both 99m Tc-EC-AMT and unlabeled AMT were rapidly taken up through the amino acid transporter LAT in vivo. A planar imaging study in the breast tumor-bearing rats was performed at 30-240 min. As there was no marked difference in tumor uptake after 90 min, images at only 30 and 90 min are displayed in Fig. 5 . In-vivo uptake blocking study showed that the uptake of 99m Tc-EC-AMT in tumors could be blocked by AMT, and thus decreased at 30 min, but then recovered at 90 min (Fig. 6) , suggesting that the best time point for imaging was 30-90 min. With respect to that, the half-life of 99m Tc is 6.02 h; therefore, studies after 6 h will not be clinically practical because of the lack of radioactivity. Our preliminary results indicate that 99m Tc-EC-AMT is suitable for imaging of breast tumors. By taking the advantages of the coordination capability of the chelator, EC-AMT could chelate various radioisotopes for both imaging and therapy, whereas FDG and other existing amino acid-based radiotracers could not. Further studies to test the specificity of 99m Tc-EC-AMT in differentiating tumors from inflammatory tissues and distinguishing tumors between before and after chemo/radiation therapy will be conducted in the future.
Conclusion
In summary, EC-AMT was synthesized and labeled with 99m Tc readily and efficiently with high radiochemical purity. In-vitro cellular uptake study showed that 99m Tc-EC-AMT transport involved the amino acid transporter system LAT. On account of its simple chemical synthesis, cost effectiveness of the isotope, and planar imaging with comparatively high T/M uptake ratios, 99m Tc-EC-AMT has the potential for tumor imaging and prediction of tumor response to chemo/radiotherapy.
